RU2424811C2 - Medication for treatment of psoriasis - Google Patents

Abstract

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, in particular for treatment of psoriasis. Medication for treatment of psoriasis, which contains solution of phospholipids in 70% ethyl alcohol and water solution of sodium deoxyribonucleate, components being taken in specified ratio.

EFFECT: medication is efficient for treatment of psoriasis.

4 ex

Description

The invention relates to medicine and can be used to effectively treat psoriasis.

An external means for skin regeneration based on a liposomal preparation containing a solution of lipids in an organic solvent and a biologically active active substance is known from the prior art (RU 2036637, A61K 7/00, 1995; RU 2303977, A61K 9/127, 2007). This drug, which may have a mild dosage form, is a cosmetic product and is not suitable for the treatment of psoriasis.

A medicament for the treatment of psoriasis in the form of a spray is also known, containing in a pharmaceutically acceptable carrier a therapeutically effective amount of the active substance (clobetasol propionate in dissolved form; calcitriol in dissolved form), the alcohol phase, at least one volatile silicone and non-volatile oil phase (RU 2007101542 A, A61K 31/593, 2008). However, the use of such a drug in the form of a spray for the treatment of psoriasis may not be effective enough.

The invention is directed to the creation of a drug based on a liposomal drug that provides effective treatment for psoriasis.

The solution to this problem is provided by the fact that the drug for the treatment of psoriasis based on the liposome preparation according to the invention contains a solution of lipids in an organic solvent and an aqueous solution of a biologically active active substance, while sodium deoxyribonucleate in the composition of liposomes is used as a biologically active active substance in the following ratio of components , wt.%:

sodium deoxyribonucleate 0.01 ÷ 0.04 phospholipids 1,0 ÷ 2,0 organic solvent - ethyl alcohol 7 ÷ 14 water rest

In addition, the solution of the problem is also ensured by the fact that the drug for the treatment of psoriasis based on the liposomal preparation according to the invention is made in a soft dosage form - ointment and contains a binder in an organic solvent and a liposomal preparation, including an aqueous solution of a biologically active active substance, while as a biologically active active substance, sodium deoxyribonucleate is used as a part of liposomes, and the binder contains the Karbopol polymer and hydraxy sodium in the following ratio, wt.%:

"Carbapol" 0.8 ÷ 1.2 sodium hydroxide no more 0,025 sodium deoxyribonucleate 0.0015 ÷ 0.0065 phospholipids 0.15 ÷ 0.32 organic solvent - ethyl alcohol 1.15 ÷ 2.30 water rest

The therapeutic effectiveness when using the claimed drug for the treatment of psoriasis is due to the fact that sodium deoxyribonucleate is an immunomodulator with a pronounced anti-inflammatory effect. In addition, the effectiveness of the preparation obtained in accordance with the invention in the form of a homogeneous suspension of liposomal vesicles, which can be used in the dosage form in the form of an aerosol or ointment, is also due to the fact that it is enclosed in a lipid shell consisting mainly of neutral and negatively charged phospholipids, a biologically active component - sodium deoxyribonucleate during external treatment of affected areas of the skin actively penetrate deep into the skin, effectively manifesting their mmunokorregiruyuschie and anti-inflammatory properties.

The claimed drug is prepared as follows. The lipid component is a phospholipid extract (for example, Lipofolk) is dissolved in an organic water-soluble solvent (for example, ethanol - 70% ethanol) to obtain a 10% concentration of phospholipids and mixed in a 1: 1 ratio with a 0.1% aqueous solution of the active substance - sodium deoxyribonucleate prepared, for example, by dissolving 0.02 wt. including sodium deoxyribonucleate in 20 wt. including distilled water), pour the mixture into a container and add the remaining amount of distilled water to obtain an aqueous suspension of liposomes with the stated ratio of components. Thus prepared drug for the treatment of psoriasis based on sodium deoxyribonucleate in the form of a liposome preparation is applied mainly in the form of an aerosol stream by spraying from a sealed container under pressure, for example, a neutral gas (air or propellant), on the affected areas of the skin.

In addition, the claimed drug can be prepared in the form of an ointment as follows:

To prepare the ointment, 500 g of ointment “Karbopol” polymer is injected into 40 l of distilled water and kept for 3 hours for maximum polymer swelling, stirred until a homogeneous homogeneous substance is formed, into which then 80 ml of a 4 M sodium hydroxide solution are added dropwise with continuous stirring. Into the obtained gel, 20% by weight (8 kg) of the liposomal component prepared according to the above technology is introduced and mixed until a soft ointment is obtained.

The claimed drug can be used both independently and in combination therapy for the treatment of psoriasis.

Example 1

Patient J., 33 years old. He was sent to the dermatological department of a clinical hospital with a diagnosis of "Common psoriasis." As an external therapy, a liposomal preparation containing 0.01 wt.% Sodium deoxyribonucleinate was obtained in the stationary stage. On day 14, itching disappeared, new papules were reduced. By day 15, plaque decay on the upper extremities began - the number of hyperpigmented areas increased. By the 17th day, the plaques on the entire affected surface completely “broke up” into separate ones and there were multiple hyperpigmented rashes. By day 18, the rash completely acquired a spotty character - the regressive stage of the psoriatic process has begun. By the time of discharge from the hospital (21 days from the start of treatment), the patient had single hyperpigmented spots in the upper limbs and trunk and multiple areas of hyperpigmentation and cyanotic red spots in the lower extremities.

Example 2

Patient M., 21 years old. In the dermatological department of the clinical hospital he was treated with a diagnosis of "Limited palmar-plantar psoriasis." As an external therapy, a liposomal preparation containing 0.025 wt.% Sodium deoxyribonucleinate was obtained in the stationary stage. On day 11, itching disappeared, new papules were reduced. By the 14th day, the plaques on the entire affected surface were completely “broken up” into separate ones and multiple hyperpigmented rashes were observed. By the time of discharge from the hospital (20 days from the start of treatment), the patient had single hyperpigmented spots in the palms and multiple areas of hyperpigmentation and cyanotic red spots in the soles.

Example 3

Patient S., 45 years old, was treated in the dermatological department with a diagnosis of "Common pustular psoriasis." As an external therapy, a liposomal preparation containing 0.04 wt.% Sodium deoxyribonucleinate was obtained in the stationary stage. By the 16th day from the start of treatment, all plaques became flat, cleared of purulent discharge, the color of bright red became pale pink. Full resolution of the rash occurred by 21 days from the start of treatment.

Example 4

Patient E., 36 years old, complained of itchy bright pink flaky plaques in the scalp, trunk, upper and lower extremities. He was previously diagnosed with Common Psoriasis. As an external therapy, in the stationary stage, I treated the areas of the affected skin with an ointment containing a liposome preparation of 0.003 wt.% Sodium deoxyribonucleinate. By the 11th day from the start of treatment, 40% of papular exanthema acquired a flat shape; a decrease in the total number of papular-plaque elements was noted. By the 15th day from the start of treatment, all plaques became flat, the color of bright red became pale pink. Full resolution of the rashes came on the 19th day from the start of treatment.

Claims (1)

A drug for the treatment of psoriasis based on sodium deoxyribonucleate, characterized in that it contains a solution of phospholipids in 70% ethanol and an aqueous solution of sodium deoxyribonucleate, while the components are taken in the following ratio, wt.%:
sodium deoxyribonucleate 0.01-0.04 phospholipids 1.0-2.0 70% ethyl alcohol 7.0-14.0 water rest